Lucinda Quan
Founder bij ALIGOS THERAPEUTICS, INC.
Vermogen: 377 109 $ op 31-03-2024
Actieve functies van Lucinda Quan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALIGOS THERAPEUTICS, INC. | Founder | 05-02-2018 | - |
General Counsel | 01-03-2018 | - |
Loopbaan van Lucinda Quan
Eerdere bekende functies van Lucinda Quan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MERCK & CO., INC. | Corporate Officer/Principal | 01-01-2016 | 01-04-2018 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | General Counsel | 01-11-2013 | 01-01-2016 |
INTERMUNE INC | General Counsel | 01-09-2004 | 01-11-2013 |
Opleiding van Lucinda Quan
University of California, Los Angeles | Graduate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Operationeel
General Counsel | 3 |
Founder | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
ALIGOS THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
InterMune, Inc.
InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Beurs
- Insiders
- Lucinda Quan
- Ervaring